SynDevRx, Inc.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Methionine aminopeptidase 2 (MetAP2, inhibitor)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
EvexomostatPhase 1/2HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
Est. primary completion 2026-12 · NCT05455619 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.